Roche has secured US Food and Drug Administration (FDA) approval for Wilserdly (giredestrant) in combination with everolimus to treat adults with a particularly aggressive, treatment-resistant form of breast cancer.
This marks a significant advance for patients whose disease progresses despite endocrine therapy.
The approval covers patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer, identified through an FDA-authorised test. It applies to patients whose cancer has returned during or after adjuvant endocrine therapy, or progressed after at least one endocrine-based treatment regimen in the metastatic setting.
The decision addresses a major unmet medical need. Up to 40% of patients with hormone receptor (HR)-positive metastatic breast cancer develop ESR1 mutations, which drive resistance to endocrine therapy and fuel disease progression.
Wilserdly, combined with everolimus, targets two distinct signalling pathways to tackle treatment resistance. The combination also offers the advantage of an entirely oral treatment regimen, eliminating the need for injections and potentially reducing the disruption to patients' daily lives.
"For patients with ESR1-mutated advanced breast cancer, the development of resistance to endocrine therapy remains a substantial challenge - often requiring more intensive treatment,” said Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development.
“By pairing potent oestrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home.”
The FDA approval is backed by positive results from the Phase III evERA Breast Cancer study, published in The New England Journal of Medicine.
In patients with ESR1-mutated, ER-positive, HER2-negative locally advanced or metastatic breast cancer whose disease had progressed following treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor, Wilserdly combined with everolimus significantly extended progression-free survival.
The all-oral combination reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus (stratified hazard ratio: 0.38; 95% confidence interval: 0.27–0.54; p<0.0001).¹˒⁵
The findings point to a potentially important new treatment option for patients whose cancers have stopped responding to existing endocrine-based therapies.
“Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow,” said Erica L. Mayer, Director of Breast Cancer Clinical Research at the Dana-Farber Cancer Institute.
“The evERA trial demonstrates that the oral giredestrant combination regimen directly targets the primary genomic drivers of resistance, offering patients prolonged disease control through a fully oral therapeutic option.”
Roche described the FDA decision as a major milestone in its oncology portfolio, with ambitions to expand Wilserdly's role across different stages of breast cancer treatment.
“For more than three decades, Roche has transformed care across oncology, and this first approval for Wilserdly marks a pivotal leap forward in addressing aggressive, treatment-resistant breast cancer,” said Teresa Graham, Chief Executive Officer, Roche Pharmaceuticals.
“We remain focused on maximising the clinical impact of Wilserdly across the continuum of care, including early-stage disease.”
The company is also seeking approval for Wilserdly as an adjuvant treatment for adults with ER-positive, HER2-negative stage I, II and III breast cancer who face an intermediate to high risk of recurrence.
If approved, Wilserdly could become the first new adjuvant endocrine therapy in more than 20 years, potentially establishing a new standard of care for patients with early-stage breast cancer.
Roche said its broader Wilserdly clinical development programme spans multiple treatment settings and stages of disease. Additional regulatory submissions and development activities are also underway in markets outside the United States, as the company seeks to extend access to the treatment for more people living with HR-positive breast cancer.